Effect of increased opiate exposure on three years neurodevelopmental outcome in extremely preterm infants

Standard

Effect of increased opiate exposure on three years neurodevelopmental outcome in extremely preterm infants. / Giordano, V; Deindl, P; Fuiko, R; Unterasinger, L; Waldhoer, T; Cardona, F; Berger, A; Olischar, M.

in: EARLY HUM DEV, Jahrgang 123, 08.2018, S. 1-5.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{7424538eaf834b4993c6172afc693a3d,
title = "Effect of increased opiate exposure on three years neurodevelopmental outcome in extremely preterm infants",
abstract = "BACKGROUND: International guidelines recommend the use of item based scales for the assessment of pain and sedation. In our previous study, the implementation of the Neonatal Pain Agitation and Sedation Scale (N-PASS), and the associated systematic assessment and treatment of pain and sedation reduced pain and over-sedation in our intervention group, but lead to a significant increase of individual opiate exposure. This increased opiate exposure was not associated with impaired motor and mental development at one year of age. As one-year follow-up is not necessarily representative for future outcomes, we retested our sample at three years of age.METHODS: Fifty-three patients after (intervention group) and 61 before implementation (control group) of the N-PASS and the Vienna Protocol for the Management of Neonatal Pain and Sedation (VPNPS), were compared for motor, mental and behavioural development at three-years follow-up using the Bayley Scales of Infant Development.RESULTS: Cumulative opiate exposure was not associated with mental (p = .31) and motor (p = .20) problems when controlling for other important medical conditions, but was associated to lower behavioural scores (p = .007). No statistically significant differences were found with regard to mental (p = .65), psychomotor (p = .12) and behavioural (p = .61) development before and after the implementation of the N-PASS and the VPNPS.CONCLUSION: Implementing a neonatal pain and sedation protocol increased opiate exposure without affecting neurodevelopmental outcome at three-years of age.",
keywords = "Journal Article",
author = "V Giordano and P Deindl and R Fuiko and L Unterasinger and T Waldhoer and F Cardona and A Berger and M Olischar",
note = "Copyright {\textcopyright} 2018 Elsevier B.V. All rights reserved.",
year = "2018",
month = aug,
doi = "10.1016/j.earlhumdev.2018.06.010",
language = "English",
volume = "123",
pages = "1--5",
journal = "EARLY HUM DEV",
issn = "0378-3782",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Effect of increased opiate exposure on three years neurodevelopmental outcome in extremely preterm infants

AU - Giordano, V

AU - Deindl, P

AU - Fuiko, R

AU - Unterasinger, L

AU - Waldhoer, T

AU - Cardona, F

AU - Berger, A

AU - Olischar, M

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2018/8

Y1 - 2018/8

N2 - BACKGROUND: International guidelines recommend the use of item based scales for the assessment of pain and sedation. In our previous study, the implementation of the Neonatal Pain Agitation and Sedation Scale (N-PASS), and the associated systematic assessment and treatment of pain and sedation reduced pain and over-sedation in our intervention group, but lead to a significant increase of individual opiate exposure. This increased opiate exposure was not associated with impaired motor and mental development at one year of age. As one-year follow-up is not necessarily representative for future outcomes, we retested our sample at three years of age.METHODS: Fifty-three patients after (intervention group) and 61 before implementation (control group) of the N-PASS and the Vienna Protocol for the Management of Neonatal Pain and Sedation (VPNPS), were compared for motor, mental and behavioural development at three-years follow-up using the Bayley Scales of Infant Development.RESULTS: Cumulative opiate exposure was not associated with mental (p = .31) and motor (p = .20) problems when controlling for other important medical conditions, but was associated to lower behavioural scores (p = .007). No statistically significant differences were found with regard to mental (p = .65), psychomotor (p = .12) and behavioural (p = .61) development before and after the implementation of the N-PASS and the VPNPS.CONCLUSION: Implementing a neonatal pain and sedation protocol increased opiate exposure without affecting neurodevelopmental outcome at three-years of age.

AB - BACKGROUND: International guidelines recommend the use of item based scales for the assessment of pain and sedation. In our previous study, the implementation of the Neonatal Pain Agitation and Sedation Scale (N-PASS), and the associated systematic assessment and treatment of pain and sedation reduced pain and over-sedation in our intervention group, but lead to a significant increase of individual opiate exposure. This increased opiate exposure was not associated with impaired motor and mental development at one year of age. As one-year follow-up is not necessarily representative for future outcomes, we retested our sample at three years of age.METHODS: Fifty-three patients after (intervention group) and 61 before implementation (control group) of the N-PASS and the Vienna Protocol for the Management of Neonatal Pain and Sedation (VPNPS), were compared for motor, mental and behavioural development at three-years follow-up using the Bayley Scales of Infant Development.RESULTS: Cumulative opiate exposure was not associated with mental (p = .31) and motor (p = .20) problems when controlling for other important medical conditions, but was associated to lower behavioural scores (p = .007). No statistically significant differences were found with regard to mental (p = .65), psychomotor (p = .12) and behavioural (p = .61) development before and after the implementation of the N-PASS and the VPNPS.CONCLUSION: Implementing a neonatal pain and sedation protocol increased opiate exposure without affecting neurodevelopmental outcome at three-years of age.

KW - Journal Article

U2 - 10.1016/j.earlhumdev.2018.06.010

DO - 10.1016/j.earlhumdev.2018.06.010

M3 - SCORING: Journal article

C2 - 29935388

VL - 123

SP - 1

EP - 5

JO - EARLY HUM DEV

JF - EARLY HUM DEV

SN - 0378-3782

ER -